Neurocrine Biosciences
NBIX
#1689
Rank
NZ$21.62 B
Marketcap
NZ$215.42
Share price
-1.13%
Change (1 day)
6.95%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total assets

Total assets on the balance sheet as of December 2025 : NZ$7.75 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total assets are NZ$7.75 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Neurocrine Biosciences - Total assets on balance sheet (from 2001 to 2025)

Total assets by year

Year Total assets Change
2025-12-31NZ$7.99 B21.28%
2024-12-31NZ$6.59 B28.25%
2023-12-31NZ$5.14 B37.81%
2022-12-31NZ$3.73 B22.96%
2021-12-31NZ$3.03 B26.21%
2020-12-31NZ$2.40 B23.98%
2019-12-31NZ$1.93 B30.97%
2018-12-31NZ$1.48 B28.61%
2017-12-31NZ$1.15 B118.42%
2016-12-31NZ$0.52 B-24.02%
2015-12-31NZ$0.69 B123.64%
2014-12-31NZ$0.31 B64.79%
2013-12-31NZ$0.18 B-20.99%
2012-12-31NZ$0.23 B34.37%
2011-12-31NZ$0.17 B-5.29%
2010-12-31NZ$0.18 B92%
2009-12-31NZ$97.5 M-52.12%
2008-12-31NZ$0.20 B-43.61%
2007-12-31NZ$0.36 B-34.7%
2006-12-31NZ$0.55 B-21.75%
2005-12-31NZ$0.70 B-2.86%
2004-12-31NZ$0.72 B-14.77%
2003-12-31NZ$0.85 B67.63%
2002-12-31NZ$0.50 B-38.94%
2001-12-31NZ$0.83 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
Pfizer
PFE
NZ$349.57 B 4,406.77%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$224.24 B 2,791.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$188.37 B 2,328.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$4.89 B-36.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$12.44 M-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.35 B-69.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ$14.42 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$32.86 B 323.64%๐Ÿ‡ฌ๐Ÿ‡ง UK